排序方式： 共有11条查询结果，搜索用时 15 毫秒
1.
《运动与健康科学(英文)》2014,3(1):52-57
Currently there are more than 13.7 million cancer survivors living in the U.S., and that figure is projected to increase by 31% in the next decade, adding another 4 million cancer survivors into the healthcare system. Cancer is largely a disease of aging, and the aging of the population will sharply raise the proportion of older cancer survivors, many of whom will be long-term survivors (5+ years post diagnosis). This review will address the potential utility of exercise to address three health problems that are of particular concern for the aging cancer survivor and the healthcare system, i.e., disability, falls, and cardiovascular disease, because the development of these age-related problems may be accelerated by cancer treatment. While there are many different modes of exercise that each produce specific adaptations, Tai Ji Quan may be a particularly suitable strategy to mitigate the development of age- and cancer-treatment-related problems. Based on studies in older adults without cancer, Tai Ji Quan produces musculoskeletal and cardiometabolic adaptations and is more easily performed by older adults due to its low energy cost and slower movement patterns. Since cancer survivors are mostly older, inactive, and often physically limited by the lingering side effects of treatment, they need to engage in safe, practical, and effective modes of exercise. The dearth of published controlled trials examining the efficacy of Tai Ji Quan to mitigate cancer-treatment-related musculoskeletal and cardiovascular side effects points to ample research opportunities to explore the application of this non-Western exercise modality to improve long-term outcomes for aging cancer survivors. 相似文献
2.
针对进展期胃癌新辅助化疗的价值在临床中的应用仍有争论,本文采用Cochrane系统评价方法,查询了国内外有关的英文及中文随机对照试验研究,以对胃癌新辅助化疗的疗效进行Meta分析,为临床决策提供依据. 相似文献
3.
目的：评价国产新福菌素对老年非小细胞肺癌（NSCLC）的疗效和不良反应。方法：选取老年NSCLC病例81例，随机分治疗组43例给予新福菌素6μg／kg（第1～4d）。卡铂（CBP）300mg／m^2（第1d），依托泊苷（VP-16）100mg（第1～4或5d）静脉滴注；对照组38例单纯使用CBP和VP—16，剂量和方法同治疗组。21～28d为一个疗程．2～3个疗程评价疗效，随访缓解期和生存期。结果：治疗组有效率为53．49％，对照组有效率为31.58％，差异有显著性（P〈0．05）；中位缓解期分别为6和4．5个月，中位生存期分别为9和7个月．一年生存率分别为39．53％（17／43）和26．32％（10／38）。结论：新福菌素联合CBP、VP—16治疗老年NSCLC有较好的临床疗效及应用价值。 相似文献
4.
Purpose To exam the relationship between HER2 over-expression and different adjuvant chemotherapies in breast cancer. Patients and Methods A total of 1625 primary breast cancer patients who received post-surgery adjuvant chemotherapy in Tianjin Cancer Hospital, China, from July 2002 to November 2005 were included in the study. Among them, 600 patients were given CMF (CTX MTX 5-Fu) regimen, 600 given CEF (CTX E-ADM 5-Fu) regimen, and 425 given anthracyclines plus taxanes regimen, with mean follow-up time of 42 months. Results In CMF treatment group, the 3-year disease free survival (DFS)in HER2 over-expressed patients was lower than that of the HER2-negative ones (89.80% vs 91.24%, P=0.0348); in node-positive subgroup, the 3-year DFS was 84.72% in HER2 over-expressed patients, and 90.18% in the HER-2-negative ones (P=0.0271).Compared to CMF regimen, anthracyclines and anthracyclines plus taxanes regimens are more effective (P＜0.05) in node-positive HER2 over-expression than those in the node-negative. Conclusion HER2 over-expression is an independent index for predicting poor prognosis and short DFS for breast cancer patients. HER2 over-expressed patients are resistant to CMF regimen chemotherapy, but sensitive to anthracyclines-based or anthracyclines plus taxanes regimen. HER2 expression can be taken as a marker for therapies in breast cancer. 相似文献
5.
Wei-qin Jiang Fang-fang Fu Yang-xia Li Wei-bin Wang Hao-hao Wang Hai-ping Jiang Li-song Teng 《Journal of Zhejiang University. Science. B》2012,13(9):663-675
Colorectal cancer remains one of the most common types of cancer and leading causes of cancer death worldwide. Although we have made steady progress in chemotherapy and targeted therapy, evidence suggests that the majority of patients undergoing drug therapy experience severe, debilitating, and even lethal adverse drug events which considerably outweigh the benefits. The identification of suitable biomarkers will allow clinicians to deliver the most appropriate drugs to specific patients and spare them ineffective and expensive treatments. Prognostic and predictive biomarkers have been the subjects of many published papers, but few have been widely incorporated into clinical practice. Here, we want to review recent biomarker data related to colorectal cancer, which may have been ready for clinical use. 相似文献
6.
Xu Q Li ZX Peng HQ Sun ZW Cheng RL Ye ZM Li WX 《Journal of Zhejiang University. Science. B》2011,12(4):247-255
This paper aims to investigate the effects of artesunate (ART) on growth and apoptosis in human osteosarcoma HOS cell line
in vitro and in vivo and to explore the possible underlying mechanisms. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. The induction of apoptosis was detected by light and transmission electron microscopy and flow cytometry.
Western blot analysis was used to investigate the related mechanisms. Nude mice were further employed to investigate the antitumour
activity of ART in vivo. MTT assay results demonstrated that ART selectively inhibits the growth of HOS cells in a dose- and
time-dependent manner. Based on the findings of light and transmission electron microscopy, Hoechst 33258 staining, and fluorescein
isothiocyanate (FITC)-annexin V staining, the cytotoxicity of ART in HOS cells occurs through apoptosis. With ART treatment,
cytosolic cytochrome c was increased, Bax expression was gradually upregulated, Bcl-2 expression was downregulated, and caspase-9 and caspase-3
were activated. Thus, the intrinsic apoptotic pathway may be involved in ART-induced apoptosis. Cell cycle analysis by flow
cytometry indicated that ART may induce cell cycle arrest at G2/M phase. In nude mice bearing HOS xenograft tumours, ART inhibited tumour growth and regulated the expressions of cleaved
caspase-3 and survivin, in agreement with in vitro observations. ART has a selective antitumour activity against human osteosarcoma
HOS cells, which may be related to its effects on induction of apoptosis via the intrinsic pathway. The results suggest that
ART is a promising candidate for the treatment of osteosarcoma. 相似文献
7.
K. Rohini Surekha Bhat P. S. Srikumar A. Mahesh Kumar 《Indian journal of clinical biochemistry : IJCB》2015,30(3):329-333
The present study was aimed at assessing alterations in serum PCT in terms of its relation to body weight gain in pulmonary tuberculosis (PTB) patients undergoing treatment. Among patients (25–75 years) diagnosed with pulmonary tuberculosis, those that were new smear positive, showed sputum conversion at the end of 2 months and were declared clinically cured at the end of 6 months, were included in the study (n = 40). Serum procalcitonin was determined by BRAHMS PCT-Q kit. Patients were divided into two study groups—Group 1 (n = 21; serum PCT > 2 ng/ml at diagnosis), Group 2 (n = 19; serum PCT > 10 ng/ml at diagnosis). Body weights of all patients were obtained at three different time points, PTB-0 (at diagnosis), PTB-2 (after 2 months of intensive treatment) and PTB-6 (after 6 months of treatment). In both groups, mean body weights at PTB-2 and PTB-6 were significantly higher than those at PTB-0 and at PTB-6 were significantly higher than those at PTB-2. However, percentage body weight gain following 2 months of intensive treatment was higher in group 1 (4.05 % gain, p < 0.01) than in group 2 (2.75 % body weight gain, p < 0.05). Thus, the percentage gain in group 1 was tending more towards the desirable minimum gain of 5 % during intensive phase. Increase in serum PCT levels in pulmonary tuberculosis is inversely associated with body weight gain during treatment. Thus, PCT could play a role in regulation of body weight gain in anorectic conditions like tuberculosis. 相似文献
8.
目的 了解TP和CP治疗卵巢癌的效果。方法 回顾性分析我院2000年5月“2005年10月收治的40例卵巢癌病例资料。结果 两组疗效及生存率比较有显著性差异。（P〈0．05）。结论 以TAX为主的联合化疗方案对卵巢癌的疗效较好，尤其是对常规治疗后复发的患者。 相似文献
9.
作者随访334例临床ⅠⅡ期乳癌,结果提示:临床ⅠⅡ期乳癌无论采用传统根治或改良根治术,其5、10年生存率无差别;但单纯改良根治术后5年复发率高于传统根治术;放疗加化疗确能提高手术后(特别是改良根治术后)5年生存率,降低5年内复发率;手术后早期放疗和/或化疗不能改善10年生存率,降低10年复发率。因此,作者认为术后无条件行化疗和放疗的乳癌患者,尽可能行传统乳癌根治术。并强调手术后特别是改良根治术后放疗加化疗的必要性。生存5年以上的患者应定期化疗,局部复发或有远处转移者应结合手术行再放疗以提高10年生存率,降低10年复发率。 相似文献
10.
Advanced primary peritoneal carcinoma： clinicopathological and prognostic factor analyses 总被引：1，自引：0，他引：1
Objective: To investigate the factors favoring a positive prognosis for advanced primary peritoneal carcinoma (PPC). Methods: Twenty-four cases meeting the criteria for PPC were analyzed retrospectively for the clinicopathologic profiles. Immunohistochemistry was used to determine the expressions of p53, Top2α, Ki-67 and Her-2/neu. Then all these clinicopathological factors and molecular markers were correlated with the prognosis. Results: There were 15 cases of primary peritoneal serous papillary carcinoma (PPSPC), 6 cases of mixed epithelial carcinoma (MEC) and 3 cases of malignant mixed Mullerian tumor (MMMT). All patients underwent cytoreductive surgery with optimal debulking achieved in 3 cases. Among those receiving first-line chemotherapy, 13 patients received the TP regimen (paclitaxel-cisplatin or carboplatin) and 7 patients received the PAC regimen (cisplatin-doxorubicin-cyclophosphamide). The median overall survival of all patients was 42 months, while the breakdown for survival time for patients with PPSPC, MMT and MEC was 44, 13 and 19 months, respectively. The expressions of p53, Top2a and Ki-67 were all demonstrated in 11 cases respectively. None showed the expression of Her-2/neu. There were significant differences in the median survival between patients with PPSPC and those with MMMT (44 months vs 13 months, P<0.05), also between patients receiving TP combination and those receiving the PAC regimen (75 months vs 28 months, P<0.05). Another significant difference in the median progression-free survival (PFS) was identified between patients with positive p53 immunostaining and those with negative p53 immunostaining (15 months vs 47 months, P<0.05), whereas age, menopausal status, residual tumor size and the other molecular factors did not significantly impact survival. Conclusion: Patients with PPC should be treated with a comprehensive management plan including appropriate cytoreductive surgery and responsive chemotherapy. Overestimating an optimal debulking surgery may not benefit survival. The pathologic subtype, chemotherapy regimen and p53 overexpression were significant prognostic factors. 相似文献